Share class: Caplin Point Laboratories Limited

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A176,011,69620,190,858 ( 26.56 %) 0 26.56 %

Major shareholders: Caplin Point Laboratories Limited

NameStocks%Valuation
24.71 %
18,778,790 24.71 % 495 M ₹
18.64 %
14,167,192 18.64 % 373 M ₹
11.91 %
9,050,000 11.91 % 239 M ₹
11.84 %
9,000,000 11.84 % 237 M ₹
May India Property Pvt Ltd.
2.785 %
2,117,000 2.785 % 56 M ₹
Government of India
2.728 %
2,073,704 2.728 % 55 M ₹
UTI Asset Management Co. Ltd. (Investment Management)
1.63 %
1,238,773 1.63 % 33 M ₹
First Dimension Holdings Pvt Ltd.
0.4868 %
370,000 0.4868 % 10 M ₹
Kiraviz Properties & Consultancy LLP
0.1973 %
150,000 0.1973 % 4 M ₹
Nippon Life India Asset Management Ltd. (Invt Mgmt)
0.0465 %
35,346 0.0465 % 931 558 ₹
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░

Breakdown by shareholder type

Individuals67.08%
Others3.47%
Governments2.73%
Institutional1.97%
Unknown24.75%

Based on 1000 largest holdings

Geographical origin of shareholders

Individuals
67.09%
India
8.11%
Hong Kong
0.03%
Switzerland
0.01%
United Kingdom
0.01%

Based on 1000 largest holdings

Logo Caplin Point Laboratories Limited
Caplin Point Laboratories Limited is an India-based pharmaceutical company with a business model catering predominantly to emerging markets of Latin America and Africa. The Company has also entered regulated markets such as the United States through its Subsidiary, Caplin Steriles Limited. The Company's operations include research & development and manufacturing of finished formulations, active pharmaceutical ingredients (APIs), clinical research, front-end generic presence in Latin America, brand marketing in Francophone Africa and a USFDA/EU-GMP approved injectable facility. In the Regulated Markets, its products include liquid & lyophilized vials, pre-filled syringes, three-pc ophthalmic droppers and pre-mix bags. In the Emerging Markets, its products include tablets, dry syrups - bottles, soft gels, capsules, suppositories, liquid syrups - bottles, liquid injectables in ampoules & vials, lyophilized vials, prefilled syringes (PFS), and emulsion injection in ampoules & vials.
Employees
3,966